The funding will be used to pay for clinical trials in the US that will be used as underlying evidence for FDA clearance of the test, the company said.
The firms will use MGI's sequencing technology and Curetis' sample prep platform and antibiotic resistance database to develop IVDs, initially for China.
The prize is awarded to research teams around the world that are attempting to develop a point-of-care test help further reduce the spread of drug-resistant bacteria.
The firm is in the process of sequencing phage genomes as well as bacterial genomes before and after phage infection, in order to develop antimicrobials.
The company hopes to raise funding this summer and has been conducting pilots with NewYork-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center.
